Valproic Acid: Uses, Side Effects, and Major Warnings

Valproic acid is one of the most widely prescribed medications in neurology and psychiatry, used primarily to control seizures, stabilize mood in bipolar disorder, and prevent migraines. First synthesized in 1882 as a laboratory solvent, its anticonvulsant properties were discovered by accident decades later, and it has since become a cornerstone treatment across several conditions.¹ But valproic acid also carries serious risks that demand close monitoring, particularly for women who are or could become pregnant.

How Valproic Acid Works

Valproic acid acts on the brain through several pathways at once, which is part of why it treats such a range of conditions. It boosts levels of GABA, the brain’s main calming chemical, which helps quiet the excessive electrical firing behind seizures.² Animal studies and measurements in human spinal fluid both confirm this GABA-raising effect.³ Beyond GABA, valproic acid blocks voltage-gated sodium channels, which are the gates that let nerve cells fire rapidly in sequence. It also inhibits histone deacetylase, an enzyme involved in gene expression, a property that has attracted interest in cancer research and neurodegenerative disease, though those applications remain experimental.²

This multi-target action is unusual among neurological drugs. Most anti-seizure medications work through one or two mechanisms. The fact that valproic acid hits several at once likely explains both its broad usefulness and its broad side-effect profile.

Epilepsy

Epilepsy is the condition valproic acid is most strongly associated with. It is effective against both generalized seizures (which involve the whole brain) and focal seizures (which start in one area), making it a go-to choice when the seizure type is unclear or when a patient has multiple seizure types.⁴ For certain syndromes like juvenile myoclonic epilepsy, valproic acid has better-documented efficacy than alternative drugs, and treatment options for generalized epilepsies remain relatively limited.⁵

Valproic acid also has an intravenous formulation, which makes it useful in hospital settings for status epilepticus, a dangerous condition where a seizure lasts too long or seizures come in rapid succession without recovery in between.⁴

Bipolar Disorder

Valproic acid is one of the standard mood stabilizers for bipolar disorder, alongside lithium. Its role here is both in treating acute manic episodes and in long-term maintenance to prevent future mood swings. In head-to-head comparisons, valproic acid and lithium often come out roughly equal: a systematic review and meta-analysis of 11 trials found that the protective effects of the two drugs were similar.⁶ That same analysis found valproic acid performed comparably to atypical antipsychotics like quetiapine and olanzapine, and to other mood-stabilizing anticonvulsants like carbamazepine and lamotrigine.⁶

The picture is not entirely clean, though. Some guideline reviews position lithium as the first-line choice, with one meta-analysis of over 16,000 participants finding lithium superior.⁷ In practice, though, multiple open-label trials and systematic reviews report comparable efficacy, and the choice between the two often comes down to a patient’s particular side-effect profile and tolerance. Valproic acid may be somewhat more effective at preventing manic episodes than depressive ones.⁶

Migraine Prevention

Valproic acid is not a painkiller for migraines that are already happening. Instead, it is taken daily to reduce how often migraines occur. A Cochrane review found that sodium valproate reduced headache frequency by about four headaches per 28-day period compared to placebo, and that divalproex sodium (a formulation that combines sodium valproate and valproic acid) more than doubled the chance of a patient seeing at least a 50 percent reduction in migraine frequency.⁸ In practical terms, you would need to treat about four to five people with valproate for one additional person to achieve that level of improvement over what a placebo would do.⁹

One interesting finding is that lower blood levels of valproic acid may actually work better for migraines than higher ones. A prospective study found that patients with lower serum levels saw their monthly attack frequency drop from about 3.5 to 2.0, while those with higher levels saw a smaller reduction.¹⁰ This suggests the dose needed for migraine prevention is lower than what is typically required for seizure control, which could mean fewer side effects for migraine patients.

Common Side Effects

The most frequently reported side effects are digestive problems, tremor, and weight gain.¹¹ The nausea, stomach cramps, and diarrhea tend to be worst when first starting the drug or after a dose increase, and often improve over time or with extended-release formulations that are gentler on the stomach.

Weight gain deserves special mention because it is one of the most common reasons people want to stop the medication. A randomized controlled trial confirmed that people on valproic acid gained weight compared to placebo, with increased cravings for high-fat foods and more binge eating behavior emerging over the study period.¹² The weight gain does not appear to be caused by decreased physical activity. People on valproic acid actually maintained or increased their activity levels, which points toward changes in appetite and food cravings as the driver rather than lethargy.

Hair thinning is another side effect that patients frequently notice, though it is usually temporary. Other common complaints include drowsiness, dizziness, and cognitive sluggishness, which many people describe as a mental fog.

Thrombocytopenia

Valproic acid can lower platelet counts, a condition called thrombocytopenia. In larger studies, this occurred in roughly 12 to 18 percent of patients on valproate.¹³ Risk factors include older age, female sex, and higher doses. Most cases are mild and discovered on routine blood work rather than through symptoms, but if platelet counts drop enough, you can bruise easily or have trouble stopping bleeding from cuts. This is one of the main reasons your doctor orders periodic blood tests while you are on this medication.

Free Drug Levels and Side Effects

A portion of valproic acid circulates in the blood bound to proteins and is inactive. The “free” fraction is the part that actually reaches the brain and causes both therapeutic effects and side effects. Research has found that a free valproic acid concentration above roughly 15 micrograms per milliliter has the greatest ability to predict thrombocytopenia, with strong specificity for identifying who is at risk.¹⁴ This is worth knowing because your total blood level could look normal while your free level is high, especially if you are on other medications that compete for those same protein-binding spots, or if you have low albumin from liver disease or malnutrition.

Pregnancy and Fetal Harm

This is the biggest safety concern with valproic acid, and it is not subtle. Valproic acid is one of the most teratogenic medications in common use, meaning it causes birth defects when taken during pregnancy. The risks include neural tube defects like spina bifida, heart malformations, and craniofacial abnormalities. Beyond structural birth defects, prenatal exposure affects neurodevelopment.

A large study published in the New England Journal of Medicine measured autism spectrum disorder incidence in children born to mothers with epilepsy. Among children exposed to valproate in the womb, the incidence was 10.5 percent, compared to 4.2 percent in children whose mothers had epilepsy but took no anti-seizure medication. For context, lamotrigine, another commonly used anti-seizure drug, showed an incidence of 4.1 percent, essentially identical to no drug exposure. After adjusting for other factors, valproate exposure carried a hazard ratio of 2.67, meaning roughly two and a half times the risk.¹⁵

Because of this evidence, regulatory agencies in Europe have introduced a mandatory Pregnancy Prevention Programme for valproate. The drug is now contraindicated in pregnancy and in women of childbearing potential unless they are enrolled in the program, which includes documented informed consent and an ongoing contraception plan.¹⁶ The FDA in the United States classifies it as Pregnancy Category X. If you are a woman of reproductive age and your doctor suggests valproic acid, you should expect a thorough conversation about contraception and, if relevant, about switching to a safer alternative before any planned pregnancy.

Liver Toxicity

Valproic acid is processed by the liver, and in rare cases it can cause severe hepatotoxicity that leads to liver failure. The risk is highest in children under two years old, especially those on multiple anti-seizure medications, and in the first six months of treatment. Warning signs include persistent nausea, vomiting, abdominal pain, loss of appetite, swelling, and unusual fatigue. Periodic liver function tests are standard practice during treatment.

One group at extremely high risk deserves specific mention. People with POLG mutations, a type of mitochondrial DNA disorder, should never take valproic acid. A systematic analysis of 102 POLG patients who were exposed to valproate found that 89 percent experienced adverse reactions, 85 percent developed hepatotoxicity, and 52 percent died.¹⁷ All patients with reported genotypes carried recessive POLG variants. Even liver transplantation had poor outcomes in this group, with 40 percent dying after the procedure. POLG testing is now recommended before starting valproic acid in young children with unexplained seizures, though in practice it is not always performed.

Hyperammonemic Encephalopathy

Valproic acid can cause ammonia levels in the blood to rise, sometimes dramatically, even when liver function tests look completely normal. This is one of the trickier side effects because doctors may not think to check ammonia if the standard liver panel comes back fine. When ammonia builds up enough, it leads to a condition called hyperammonemic encephalopathy: confusion, lethargy, vomiting, and in severe cases, coma.

One mechanism behind this is carnitine depletion. Valproic acid interferes with carnitine metabolism, and carnitine is needed to clear ammonia through normal biochemical pathways. A case report described a patient with bipolar disorder whose ammonia level rose to nearly 400 micromoles per liter (normal is under 35) while on valproate, despite normal liver function. The patient’s free carnitine level was critically low. Stopping valproate and supplementing with L-carnitine resolved the encephalopathy.¹⁸

This risk increases with higher doses, longer duration of treatment, and when valproic acid is combined with other anti-seizure medications (particularly topiramate, which independently raises ammonia). If you or a family member on valproic acid develops unexplained confusion or drowsiness, an ammonia level is an important test to request.

Pancreatitis

Acute pancreatitis is a rare but potentially fatal complication. A systematic review of published cases found that the diagnosis typically occurred about 11 months after starting valproic acid, though the range was wide. Of the cases reviewed, 84 percent recovered, but 16 percent died.¹⁹ The dose of valproic acid, the patient’s age, and sex did not predict who would have a fatal outcome. What did predict death was the presence of pancreatic necrosis on imaging: 84 percent of fatal cases showed necrosis, compared to 26 percent of survivors.¹⁹ Severe abdominal pain, especially if it radiates to the back, warrants immediate evaluation in anyone on this drug.

Drug Interactions to Watch

Valproic acid interacts with many medications, but a few interactions stand out because they are both common and dangerous.

Lamotrigine is frequently prescribed alongside or as an alternative to valproic acid for both epilepsy and bipolar disorder. Valproic acid slows down the body’s ability to clear lamotrigine, effectively doubling or tripling lamotrigine blood levels if the dose is not reduced accordingly. This interaction can trigger Stevens-Johnson syndrome, a severe and potentially life-threatening skin reaction.²⁰ When the two drugs are used together, lamotrigine must be started at a much lower dose and titrated slowly.

Carbapenem antibiotics (meropenem, ertapenem, imipenem) do the opposite: they drastically lower valproic acid levels, sometimes within a day or two of starting the antibiotic. This can trigger breakthrough seizures in people who were previously well controlled. If you are on valproic acid and need a carbapenem antibiotic, your medical team should consider an alternative antibiotic or add temporary seizure protection.

Aspirin and other drugs that compete for protein-binding sites can raise the free fraction of valproic acid, increasing both its effects and toxicity even when the total blood level appears unchanged. This ties back to why monitoring free levels can be more informative than total levels in certain patients.

Older Adults

Elderly patients face amplified risks with valproic acid. They tend to have lower albumin, meaning a larger percentage of the drug circulates in its active free form. They are more susceptible to thrombocytopenia. And they are more vulnerable to hyperammonemic encephalopathy, which can mimic or be confused with dementia, delirium, or stroke. A case report of a 76-year-old woman illustrated this clearly: she presented with confusion, weakness, nausea, and vomiting. Her total valproic acid level was elevated, and her ammonia climbed to over 200 micrograms per deciliter despite no obvious liver dysfunction. Her platelet count dropped simultaneously.²¹

In older adults, the clinical message is to use lower doses, monitor free drug levels rather than relying only on total levels, and maintain a high index of suspicion for ammonia-related confusion. A sudden change in mental status in an elderly person on valproic acid should prompt ammonia testing before attributing it to age-related cognitive decline.

What to Do in an Overdose

Valproic acid overdose can cause deep sedation, respiratory depression, metabolic disturbances, and dangerously high ammonia levels. Management depends on severity. For mild to moderate overdoses, supportive care and monitoring may be sufficient. In severe cases with marked neurological impairment and very high serum concentrations, hemodialysis can rapidly remove the drug from the bloodstream. L-carnitine supplementation is also used in overdose settings to help address the ammonia buildup.²² Because extended-release formulations continue releasing the drug for hours after ingestion, people who overdose on these forms need prolonged observation even if they initially look stable.

The Different Formulations

You may see valproic acid referred to by several names, which can be confusing. Valproic acid is the parent compound. Sodium valproate is its sodium salt, used in some oral and injectable formulations. Divalproex sodium (brand name Depakote in the United States) is a stable combination of sodium valproate and valproic acid in equal parts. All of these convert to valproic acid in the body and are pharmacologically equivalent. The reason different formulations exist is mainly about tolerability: divalproex sodium, particularly in its extended-release form, tends to cause less stomach upset than plain valproic acid. When reading about clinical trials, the specific formulation used varies by study, but the active drug reaching your brain is the same.

Sprinkle capsules are available for children or adults who cannot swallow tablets. These can be opened and mixed with soft food without crushing the coated granules inside, which preserves the delayed-release mechanism. Crushing regular tablets or extended-release forms defeats their purpose and can cause a sudden spike in blood levels followed by faster-than-expected clearance.

1
PubMed. The history of valproate in clinical neuroscience
2
PubMed Central. A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid – Section: Mechanism of action and actions on the CNS
3
Clinical Neuroscience Research. Valproic acid: how it works. Or not
4
PubMed Central. Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences
5
The Lancet Neurology. Valproate in the treatment of epilepsy in girls and women of childbearing potential
6
PubMed. Long-Term Treatment of Bipolar Disorder with Valproate: Updated Systematic Review and Meta-analyses
7
Clinical Psychopharmacology and Neuroscience. Lithium and Valproate in Bipolar Disorder: From International Evidence-based Guidelines to Clinical Predictors
8
Cochrane Database of Systematic Reviews. Valproate for the prophylaxis of episodic migraine in adults
9
American Family Physician. Valproate for Adult Migraine Prophylaxis
10
PubMed. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study
11
PubMed. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience
12
PubMed Central. Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial
13
PubMed Central. The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data
14
PLoS One. Safety range of free valproic acid serum concentration in adult patients
15
N Engl J Med. Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure
16
PubMed Central. Valproate and the Pregnancy Prevention Programme: exceptional circumstances
17
Journal of Medical Genetics. Evidence for sodium valproate toxicity in mitochondrial diseases: a systematic analysis
18
Clinical Psychopharmacology and Neuroscience. Valproate-induced Hyperammonemic Encephalopathy Caused by Free Carnitine Deficiency in a Patient with Bipolar Disorder: A Case Report
19
PubMed Central. Valproic Acid-Associated Acute Pancreatitis: Systematic Literature Review
20
PubMed Central. Lamotrigine-Valproic Acid Interaction Leading to Stevens-Johnson Syndrome
21
PubMed Central. Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman
22
PubMed Central. Severe Hyperammonemic Encephalopathy Following Sustained-Release Sodium Valproate Overdose: A Case Report